OneOncology Announces Strategic Acquisition of United Urology Group
In a significant move towards expanding its capabilities in cancer care, OneOncology has successfully completed the acquisition of United Urology Group (UUG). This partnership is set to bolster the delivery of high-value urology services across physician-owned practices and ambulatory surgery centers, ushering in a new era for oncology treatment in the community.
Enhanced Care Through Collaboration
The alliance between OneOncology and UUG is built on a shared culture dedicated to physician leadership and a commitment to innovation. Both organizations prioritize growth and aim to enhance the standard of care provided to patients suffering from prostate, bladder, and other genitourinary cancers. “We are incredibly excited to unite our collective expertise to drive advancements in oncology care,” stated Jeff Patton, MD, CEO of OneOncology.
Growth and Synergy
The joining forces of these two entities are particularly timely, given the rising complexity of urological cancers. Prostate cancer, in particular, has seen a steady increase in incidence rates. UUG supports over 250 providers and boasts a workforce exceeding 1,300, making it one of the nation's leading urology management services organizations.
Responding to the Rising Incidence
The American Cancer Society projects an alarming number of newly diagnosed prostate cancer cases, which is expected to reach around 300,000 in 2024. This uptick emphasizes the urgent need for responsive and expanded urological care services. “This transaction represents a pivotal moment in our journey,” noted Ian Wong, CEO of UUG, highlighting the potential to deliver greater value to patients and practitioners alike.
Operational Leadership Redefined
UUG is recognized for its operational excellence, effectively integrating advanced technology into its practices. This initiative enables UUG to expand the range of services available, thus providing comprehensive, patient-centered care. Such integration promotes collaboration among affiliated practices to maintain high standards while ensuring quality service.
A Commitment to Innovation
As OneOncology closes this acquisition, the focus shifts to combining resources and talent. “We are uniquely positioned to push the boundaries of what is achievable within the oncology space,” expressed Geoffrey Sklar, MD, Chief Medical Officer of UUG. The aim is to enhance treatment availability and effectiveness, especially for patients facing the challenges of urologic diseases and cancers.
Legal and Financial Support
In this strategic partnership, Debevoise & Plimpton LLP, alongside Sheppard Mullin, represented OneOncology legally, while Ropes & Gray LLP and McGuire Woods facilitated support for UUG's financial matters. Such comprehensive legal guidance ensures a smooth transition as both teams work toward a shared vision.
About OneOncology
Founded by community oncologists, OneOncology aims to enhance the lives of individuals battling cancer. The organization is devoted to helping community practices retain their independence while ensuring that patients benefit from accessible care. Funded by TPG and Cencora, OneOncology effectively supports its network by optimizing operations and innovating clinical practices. Today, approximately 787,000 patients receive treatment from OneOncology's network of over 1,300 cancer care professionals across more than 420 sites nationwide.
About United Urology Group
United Urology Group develops a seamless continuum of urologic care for both providers and patients. The organization is committed to enabling its affiliate practices to focus on high-quality, cost-effective urological services. With a dedicated team of over 1,500 professionals, UUG proudly serves more than 900,000 patients annually and emphasizes the importance of compassion in care.
Frequently Asked Questions
1. What does the acquisition of UUG imply for OneOncology?
The acquisition strengthens OneOncology’s portfolio by integrating advanced urology services into its network, enhancing care for patients across the nation.
2. How will UUG benefit from partnering with OneOncology?
This partnership will yield greater resources, improve operational efficiencies, and expand service offerings to better serve patients with complex urological needs.
3. What is the broader impact of this acquisition on cancer care?
The collaboration aims to address the increasing demands of cancer treatment by enhancing service delivery and ensuring high-quality care for patients.
4. Who were the legal advisors for both companies during this acquisition?
Debevoise & Plimpton LLP and Sheppard Mullin provided legal counsel for OneOncology, while Ropes & Gray LLP and McGuire Woods assisted UUG.
5. What is OneOncology's mission?
OneOncology is committed to improving the lives of those living with cancer by enabling community practices to remain independent while ensuring patient access to high-quality care.
